コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 ncluding calcitonin gene-related peptide and pituitary adenylate cyclase-activating polypeptide.
4 studies have reported that the neuropeptide pituitary adenylate cyclase activating polypeptide 38 (P
6 s were undertaken to evaluate the effects of pituitary adenylate cyclase activating polypeptide-38 (P
7 se network of nerve fibers immunoreactive to pituitary adenylate cyclase activating polypeptide-38 (P
8 tochemical studies using an antibody against pituitary adenylate cyclase activating polypeptide-38 (P
9 lin, amylin, atrial natriuretic peptide, and pituitary adenylate cyclase-activating polypeptide all s
11 n response to other neuritogenic treatments (pituitary adenylate cyclase-activating polypeptide and 1
13 la monster VIP/peptide histidine isoleucine, pituitary adenylate cyclase activating polypeptide, and
14 determine the effects of blocking glutamate, pituitary adenylate cyclase activating polypeptide, and
15 ceptors for corticotrophin-releasing factor, pituitary adenylate cyclase-activating polypeptide, and
16 inal polypeptide and the PAC(1) receptor for pituitary adenylate cyclase-activating polypeptide are m
17 situ hybridization histochemistry, including pituitary adenylate cyclase activating polypeptide, cere
18 The neurotrophic peptide PACAP (pituitary adenylate cyclase-activating polypeptide) elev
19 sence of nerve growth factor, or addition of pituitary adenylate cyclase-activating polypeptide had n
20 encoding the type I receptor (PAC1-R) of the pituitary adenylate cyclase activating polypeptide has b
21 was inhibited with high affinity by VIP and pituitary adenylate cyclase-activating polypeptide (IC50
22 egeneration did not affect the expression of pituitary adenylate cyclase-activating polypeptide mRNA
23 egulated by overlapping neural (e.g. orexin, pituitary adenylate cyclase-activating polypeptide, nitr
24 ential therapeutic potential of neuropeptide pituitary adenylate cyclase-activating polypeptides (PAC
25 The direct effects of pituitary adenylate cyclase-activating polypeptides (PAC
26 Pituitary adenylate cyclase-activating polypeptides (PAC
27 R2) that also bind a second neurokine called pituitary adenylated cyclase-activating polypeptide (PAC
28 stress (CVS) has been shown to increase BNST pituitary adenylate cyclase activating polypeptide (PACA
29 tress responses, exhibits a dense network of pituitary adenylate cyclase activating polypeptide (PACA
30 A receptor for pituitary adenylate cyclase activating polypeptide (PACA
31 d also contains a very high concentration of pituitary adenylate cyclase activating polypeptide (PACA
32 We evaluated the 38-amino-acid variant of pituitary adenylate cyclase activating polypeptide (PACA
33 Pituitary adenylate cyclase activating polypeptide (PACA
34 Alternative splicing of two exons of the rat pituitary adenylate cyclase activating polypeptide (PACA
35 Pituitary adenylate cyclase activating polypeptide (PACA
36 Pituitary adenylate cyclase activating polypeptide (PACA
37 Genes coding for the neuropeptide hormone pituitary adenylate cyclase activating polypeptide (PACA
38 We identified the neuropeptide, pituitary adenylate cyclase activating polypeptide (PACA
39 We now report that the endogenous peptide, pituitary adenylate cyclase activating polypeptide (PACA
40 Pituitary adenylate cyclase activating polypeptide (PACA
41 Bath application of pituitary adenylate cyclase activating polypeptide (PACA
42 ng these, recent evidence has suggested that pituitary adenylate cyclase activating polypeptide (PACA
43 Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase activating polypeptide (PACA
44 Pituitary adenylate cyclase activating polypeptide (PACA
45 ed the effects of two related neuropeptides, pituitary adenylate cyclase-activating polypeptide (PACA
46 that maxadilan is a selective agonist of the pituitary adenylate cyclase-activating polypeptide (PACA
47 Pituitary adenylate cyclase-activating polypeptide (PACA
48 The pituitary adenylate cyclase-activating polypeptide (PACA
49 anscription, a receptor for the neuropeptide pituitary adenylate cyclase-activating polypeptide (PACA
50 Pituitary adenylate cyclase-activating polypeptide (PACA
51 The vasoactive intestinal peptide/pituitary adenylate cyclase-activating polypeptide (PACA
52 We now report that pituitary adenylate cyclase-activating polypeptide (PACA
53 Pituitary adenylate cyclase-activating polypeptide (PACA
54 Pituitary adenylate cyclase-activating polypeptide (PACA
55 Pituitary adenylate cyclase-activating polypeptide (PACA
56 tivating polypeptide type I receptor (PAC1), pituitary adenylate cyclase-activating polypeptide (PACA
57 There is a deficit of pituitary adenylate cyclase-activating polypeptide (PACA
58 sing thyrotropin-releasing hormone (TRH) and pituitary adenylate cyclase-activating polypeptide (PACA
59 photopigment melanopsin and the neuropeptide pituitary adenylate cyclase-activating polypeptide (PACA
60 recently found higher circulating levels of pituitary adenylate cyclase-activating polypeptide (PACA
61 Pituitary adenylate cyclase-activating polypeptide (PACA
62 Pituitary adenylate cyclase-activating polypeptide (PACA
63 Pituitary adenylate cyclase-activating polypeptide (PACA
64 During corticogenesis, pituitary adenylate cyclase-activating polypeptide (PACA
65 The pituitary adenylate cyclase-activating polypeptide (PACA
66 for neuroendocrine cell neuritogenesis, and pituitary adenylate cyclase-activating polypeptide (PACA
67 Pituitary adenylate cyclase-activating polypeptide (PACA
68 Pituitary adenylate cyclase-activating polypeptide (PACA
69 ecretin/glucagon family of related peptides, pituitary adenylate cyclase-activating polypeptide (PACA
70 Pituitary adenylate cyclase-activating polypeptide (PACA
71 we show that intracerebral administration of pituitary adenylate cyclase-activating polypeptide (PACA
72 The pituitary adenylate cyclase-activating polypeptide (PACA
73 ine whether endogenous neuropeptides such as pituitary adenylate cyclase-activating polypeptide (PACA
74 ides calcitonin gene-related peptide (CGRP), pituitary adenylate cyclase-activating polypeptide (PACA
75 Pituitary adenylate cyclase-activating polypeptide (PACA
76 Pituitary adenylate cyclase-activating polypeptide (PACA
77 ellular PVN neurons are richly innervated by pituitary adenylate cyclase-activating polypeptide (PACA
78 vasoactive intestinal peptide (VIP) and the pituitary adenylate cyclase-activating polypeptide (PACA
79 The potential connection between pituitary adenylate cyclase-activating polypeptide (PACA
80 Pituitary adenylate cyclase-activating polypeptide (PACA
81 Two GPCR ligands, adenosine and pituitary adenylate cyclase-activating polypeptide (PACA
82 Given that the pituitary adenylate cyclase-activating polypeptide (PACA
83 Here we report that gradients of pituitary adenylate cyclase-activating polypeptide (PACA
84 Recent work indicates that pituitary adenylate cyclase-activating polypeptide (PACA
85 s of vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACA
86 Pituitary adenylate cyclase-activating polypeptide (PACA
87 the vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACA
88 Pituitary adenylate cyclase-activating polypeptide (PACA
89 The neuropeptides pituitary adenylate cyclase-activating polypeptide (PACA
90 In the embryo, pituitary adenylate cyclase-activating polypeptide (PACA
91 Pituitary adenylate cyclase-activating polypeptide (PACA
92 Growing evidence suggests that the pituitary adenylate cyclase-activating polypeptide (PACA
93 In addition, pituitary adenylate cyclase-activating polypeptide (PACA
94 P (SP), vasoactive intestinal peptide (VIP), pituitary adenylate cyclase-activating polypeptide (PACA
95 Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACA
96 tudies examined changes in the expression of pituitary adenylate cyclase-activating polypeptide (PACA
97 h as vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACA
98 xpression of the paracrine signaling hormone pituitary adenylate cyclase-activating polypeptide (PACA
99 The present study investigated the origin of pituitary adenylate cyclase-activating polypeptide (PACA
100 We now describe expression and functions of pituitary adenylate cyclase-activating polypeptide (PACA
101 vasoactive intestinal peptide (VIP) and the pituitary adenylate cyclase-activating polypeptide (PACA
102 nce and potential origin of the neuropeptide pituitary adenylate cyclase-activating polypeptide (PACA
103 ides vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACA
104 l peptide (VIP) and the structurally related pituitary adenylate cyclase-activating polypeptide (PACA
105 ides vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACA
106 ides vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACA
107 The pituitary adenylate cyclase-activating polypeptide (PACA
108 P) and the structurally related neuropeptide pituitary adenylate cyclase-activating polypeptide (PACA
109 croenvironment, and the structurally related pituitary adenylate cyclase-activating polypeptide (PACA
110 Vasoactive intestinal peptide (VIP) and the pituitary adenylate cyclase-activating polypeptide (PACA
111 vasoactive intestinal peptide (VIP) and the pituitary adenylate cyclase-activating polypeptide (PACA
112 previously that high-affinity receptors for pituitary adenylate cyclase-activating polypeptide (PACA
113 Pituitary adenylate cyclase-activating polypeptide (PACA
114 Pituitary adenylate-cyclase-activating polypeptide (PACA
115 The G protein-coupled pituitary adenylate cyclase-activating polypeptide recep
116 oduction mediated by the multifunctional rat pituitary adenylate cyclase-activating polypeptide recep
117 wth hormone-releasing hormone, incretin, and pituitary adenylate cyclase-activating polypeptide recep
118 ivator protein 1 site-containing gene, PAC1 (pituitary adenylate cyclase-activating polypeptide recep
119 gative for the vasoactive intestinal peptide/pituitary adenylate cyclase-activating polypeptide recep
120 imulated increases in intracellular cAMP and pituitary adenylate-cyclase activating polypeptide recep
121 The neurotransmitter pituitary adenylate cyclase-activating polypeptide stimu
122 dministration of the anorectic neuropeptide, pituitary adenylate cyclase activating polypeptide, stro
123 hallenged with the endogenous agonist of the pituitary adenylate cyclase-activating polypeptide type
124 ypeptide, stromal-derived factor-1alpha, and pituitary adenylate cyclase-activating polypeptide, whic
125 Chemicals, such as glutamate and pituitary adenylate cyclase activating polypeptide, whos
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。